HOME › DRUGS › LIXISENATIDE
ACTIVE SUBSTANCE / INN

LIXISENATIDE

Brand name(s): Lyxumia, SOLIQUA 100/33, ADLYXIN
FDA LISTED
EMA LISTED
PRESCRIPTION
WITHDRAWN
Diabetes Mellitus, Type 2
BLA208471
ACTIVE SUBSTANCE
Lixisenatide
REGULATORS
FDA · EMA
SPONSORS / MAH
Sanofi Winthrop Industrie, SANOFI-AVENTIS US
TOTAL APPLICATIONS
3
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
SOLIQUA 100/33BLA208673SANOFI-AVENTIS USPrescription
ADLYXINBLA208471SANOFI-AVENTIS USPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
LyxumiaSanofi Winthrop IndustrieWithdrawn31/01/2013Diabetes Mellitus, Type 2

FULL INTELLIGENCE ON LIXISENATIDE

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →